ENTOD Pharmaceuticals, a leading name in ophthalmic, ENT, and dermatology medicines, has announced a series of advanced research and product breakthroughs, reinforcing India’s position as a hub for pharmaceutical innovation.

Driven by its state-of-the-art R&D facility in Mumbai, the company’s latest advancements reflect a strong emphasis on indigenous research that meets global regulatory standards while addressing unmet clinical needs. The initiatives span high-impact therapeutic areas, with potential to influence both domestic healthcare delivery and global treatment practices.

Among its most significant achievements is the development of a world-first prescription eye drop designed to slow the progression of myopia in children aged 6–12, a growing public health concern. This innovation further strengthens ENTOD’s leadership in paediatric ophthalmology and corneal therapies. The company’s sustained investment in corneal health research has also led to preservative-free, biocompatible ophthalmic solutions aimed at treating ocular surface disorders, keratitis, and enhancing corneal healing.

In dermatology, ENTOD has introduced a collagen-based transdermal gel serum engineered for deep skin regeneration. Incorporating bioactive collagen peptides, plant-derived actives, and skin-mimetic delivery systems, the formulation promotes collagen synthesis, accelerates skin repair, and improves elasticity—positioning the brand ahead of international competitors in science-driven skincare.

“Our commitment lies in bridging critical gaps in healthcare through scientific innovation,” said Nikkhil K Masurkar, CEO, ENTOD Pharmaceuticals. “From redefining myopia management to advancing regenerative skincare, we aim to deliver solutions that not only meet global standards but also address the specific needs of Indian patients.”

Also read: SSII Partners with SMSIMSR to Launch South India’s Premier Robotic Cardiac Surgery & Training Hub

These R&D milestones form part of ENTOD’s India-first innovation strategy, aimed at creating affordable, globally compliant, and accessible treatments. With a presence in over 67 countries and a portfolio of more than 300 medicines, the company continues to scale its international footprint while remaining anchored in homegrown scientific expertise and patient-centric design.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!